PolarityTE (COOL) is a commercial-stage biotechnology and regenerative biomaterials company focused on bringing to market a range of regenerative tissue products and biomaterials.
The company believes that its PolarityTE platform technology can potentially address the issues currently being faced by regenerative medicine and cell therapy markets. Its TE platform starts with a piece of the patient’s healthy tissue and from this small piece creates a propagating product that’s designed to stimulate the patient’s own cells to regenerate the target tissue.
In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.
Two of the five analysts covering Progenics Pharmaceuticals (PGNX) in June have given the stock “buy” ratings, while three have given it “strong buy” ratings. The mean rating for the stock is 1.4, and its target price is $14.2.
In June, 15 of the 17 analysts covering Sarepta Therapeutics (SRPT) have given it “buy” or higher ratings, while two analysts have given the stock “hold” ratings. The mean rating for the stock is 1.88, and its target price is $130.88.
In June, five of the 11 analysts covering Alkermes (ALKS) have given it “buy” or higher ratings, while six have given it “hold” ratings. The mean rating for the stock is 2.36, and its target price is $55.18.
In the next part of the series, we’ll take a look at the financial performance of PolarityTE.